Developer docs
API playgroundTry for free, no card

Search company profiles

Denovo Sciences

Full company profile

uuid0004jnu

Namestring
Denovo Sciences
Legal namestring
Denovo Sciences
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Denovo Sciences is a private AI-driven drug discovery company headquartered in Yerevan, Armenia, founded in 2019. The company builds a proprietary computational platform for structure-based small-molecule drug design that replaces traditional high-throughput screening and library-based virtual screening with first-principles molecular generation. Its integrated platform comprises five purpose-built AI engines: Proteus for optimal protein conformation selection, Q-Pocket for binding pocket analysis using quantum-annotated hotspot clouds, the Denovo Platform for de novo molecule generation using generative AI and reinforcement learning, HADES (Holistic AI-based Drug-likeness Estimation System) for evaluating 100+ physicochemical, ADMET, and structural features, and Synthony for retrosynthesis planning using a building-block-first paradigm. Validated performance benchmarks include 50,000 compounds per week generation throughput, 89.1% drug-likeness prediction accuracy on external datasets, 74% top-1 retrosynthesis accuracy on USPTO50k, and experimentally confirmed in vitro and in vivo anti-influenza activity.

The company serves pharmaceutical companies, biotechnology firms, and academic research institutions seeking to accelerate early-stage drug discovery, particularly for targets where conventional and AI-based methods have struggled. It monetizes through three channels: software licensing (cloud, API, or on-premise deployment on a subscription basis), discovery services (hit finding, lead finding, lead optimization), and co-discovery/shared development partnerships with shared risk and licensing economics. Strategic partners include Flagship Pioneering, University of Oxford, Weill Cornell Medicine, and CIRI, with three co-founders (CEO Hovakim Zakaryan, CAIO Vardan Harutyunyan, CTO Mher Matevosyan) and an advisory board of senior pharma and AI veterans from GSK, J&J, and Insilico Medicine.

As of the available data, the company has 11-50 employees, has tested 300+ AI-generated molecules across 6 drug discovery programs with a 30% average hit rate, and operates on disclosed funding of approximately $626,236 across four rounds since 2020. No customer logos, ARR, or revenue figures are publicly disclosed.

Short descriptiontext

Denovo Sciences is an Armenia-based AI drug discovery company building a proprietary platform of five integrated engines for de novo small-molecule design, serving pharmaceutical and biotechnology partners via software licensing, discovery services, and co-development partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersYerevan, Armenia
HQ citystring
Yerevan
HQ countrystring
Armenia
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, computational drug design, small-molecule therapeutics, generative molecular design, structure-based drug discovery
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
AI Drug Discovery Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software Licensing
TypeSubscription Recurring
Description

Access to proprietary AI-powered drug discovery technologies via cloud-based solutions, API integration, or on-premise deployment. Provides flexible deployment options for partners.

denovosciences.ai
2Discovery Services
TypeProfessional Services
Description

End-to-end drug discovery support including hit finding, lead finding, and lead optimization services leveraging the AI-driven platform.

denovosciences.ai
3Co-Discovery/Shared Development Partnerships
TypeLicensing Royalties
Description

Joint discovery and advancement of promising candidates from hit to preclinical stages with partners, enabling shared risk and reward in drug development.

denovosciences.ai
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Denovo Platform
Description

AI-powered generative engine for small-molecule drug discovery, providing integrated molecular design, evaluation, and optimization workflows.

denovosciences.ai
+4 more records
Core offering1 text field

Denovo Sciences builds an AI-powered computational platform for structure-based small-molecule drug discovery. The integrated platform combines proprietary generative AI, retrosynthesis prediction (Synthony), drug-likeness evaluation (HADES), and target/binding-pocket analysis (Proteus, Q-Pocket) to design, evaluate, and prioritize novel drug-like compounds de novo within target binding pockets. The company also delivers discovery services and co-development partnerships to pharmaceutical and biotech clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 30% average hit rate across drug discovery programs
+3 more records
Product overview1 text field

Denovo Sciences offers an AI-powered drug discovery platform comprising a core Denovo Platform generative engine plus multiple integrated modules: HADES for drug-likeness evaluation (100+ features), Synthony for retrosynthesis planning, Q-Pocket for binding pocket analysis, and Proteus for target conformation selection. These modules work together in an end-to-end workflow from target selection through synthesizable molecule generation and prioritization.

Product and service8 records
1Denovo Platform
CategoryAI Drug Discovery Platform
Description

Core AI-powered generative engine platform for de novo small-molecule drug discovery; generates novel, synthesizable, drug-like compounds from first principles within target binding pockets, producing up to 50K compounds per week with 100% chemical validity. Sold to pharmaceutical and biotech partners via cloud, API, or on-premise deployment.

2HADES (Holistic AI-based Drug-likeness Estimation System)
CategoryAI Drug Discovery Software Module
Description

Proprietary engine for rapid drug-likeness evaluation that integrates 100+ structural, physicochemical, ADMET, and chemical-alert features into a unified score with detailed rationales; assesses 20 molecules per second at 89.1% accuracy on external datasets. Used to prioritize generated compounds for drug development.

3Synthony
CategoryAI Drug Discovery Software Module
Description

AI-driven retrosynthesis platform using a building-block-first paradigm to predict synthon sets from target structures, construct forward synthesis trees from purchasable building blocks, and score routes on feasibility, availability, cost, and commercial viability (74% top-1 accuracy on USPTO50k).

4Q-Pocket
CategoryAI Drug Discovery Software Module
Description

Automated toolkit for binding pocket conformation selection using quantum-annotated hotspot clouds; benchmarks conformations against functional criteria and delivers sub-minute extraction and featurization for de novo generation readiness.

5Proteus
CategoryAI Drug Discovery Software Module
Description

Proprietary platform that systematically analyzes and benchmarks all available protein conformations in the Protein Data Bank against known active compounds and decoys to recommend optimal target conformations for structure-based drug design.

6Discovery Services
CategoryDiscovery Services
Description

End-to-end drug discovery service engagements including hit finding, lead finding, and lead optimization delivered to pharmaceutical and biotech partners using the Denovo AI platform.

7Co-Discovery / Shared Development Partnerships
CategoryPartnership / Co-Development
Description

Joint discovery and advancement partnerships where Denovo and a partner share risk and reward in moving candidates from hit stage to preclinical, combining Denovo's AI capabilities with partner resources and domain expertise.

8Software Licensing (Cloud / API / On-Premise)
CategorySoftware Licensing
Description

Licensed access to the Denovo Platform, HADES, Synthony, Q-Pocket, and Proteus technologies delivered via cloud-based solutions, API integration into partner workflows, or on-premise deployment for organizations with data sovereignty or integration requirements.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Flagship Pioneering is a prominent life sciences venture firm and innovation studio. The nature of the partnership with Denovo Sciences suggests strategic collaboration in the drug discovery space, potentially involving funding and strategic guidance for AI-powered pharmaceutical development.

2CIRI
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CIRI appears to be a research institution or center involved in infectious disease research. The partnership likely focuses on collaborative antiviral drug discovery projects utilizing Denovo's AI platform.

denovosciences.ai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Chuv appears to be a research institution (likely referencing Chuvashia or a specific research center). The partnership enables access to academic research capabilities and validates the scientific rigor of Denovo's platform through institutional collaboration.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

University of Oxford is one of the world's leading research universities. The partnership provides academic validation, research collaboration opportunities, and access to cutting-edge scientific expertise in structural biology and drug discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Weill Cornell Medicine is a leading medical research institution. The partnership supports translational research initiatives and provides clinical perspective for drug development programs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in AI-driven small-molecule drug discovery. Both companies combine generative chemistry, target ID, and predictive ADMET into end-to-end pipelines; Insilico's former CAIO (Artur Kadurin) sits on Denovo's advisory board, underscoring direct comparability.

TypeDirect peer
Description

Operates a physics-based computational chemistry platform (including FEP+ and LiveDesign) that overlaps directly with Denovo's structure-based design and molecular modeling capabilities for pharma R&D.

TypeDirect peer
Description

AI-native drug discovery company combining high-throughput biology with machine learning to drive small-molecule pipelines; comparable as an end-to-end generative discovery platform targeting pharma partnerships and internal pipeline development.

TypeDirect peer
Description

Pioneer in AI-driven small-molecule drug design with an end-to-end platform and pharma co-discovery partnerships; directly comparable to Denovo's generative chemistry plus discovery services model.

TypeDirect peer
Description

AI small-molecule discovery platform serving pharma partners via software licensing and co-discovery — directly comparable GTM and technology footprint to Denovo's structure-based generative approach.

TypeDirect peer
Description

Combines AI, physics-based modeling, and robotic synthesis for small-molecule drug discovery; directly comparable on the integration of generative design with retrosynthesis and drug-likeness assessment (HADES/Synthony equivalents).

7Iambic Therapeutics
TypeEmerging player
Description

Earlier-stage AI drug-discovery platform with comparable generative chemistry and physics-based modeling capabilities; overlaps with Denovo's structure-based design and ADMET prediction stack.

8Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-backed AI-drug-discovery venture building an integrated platform from target ID to molecule design; broader in scope and capital but a comparable end-to-end generative drug-discovery vision.

TypeBroad incumbent
Description

Established AI-drug-discovery company combining knowledge graphs with ML to identify targets and small molecules; comparable in target-to-molecule scope, though typically more target-ID focused than Denovo's de novo design emphasis.

TypeEmerging player
Description

AI-driven small-molecule discovery using integrated omics and chemistry ML; overlaps with Denovo's pharma partnership and indication-pivot strategy at similar early-stage scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Denovo Sciences

AI Drug Discovery Softwaredenovosciences.ai

Denovo Sciences is an Armenia-based AI drug discovery company building a proprietary platform of five integrated engines for de novo small-molecule design, serving pharmaceutical and biotechnology partners via software licensing, discovery services, and co-development partnerships.

What Denovo Sciences does

Denovo Sciences is a private AI-driven drug discovery company headquartered in Yerevan, Armenia, founded in 2019. The company builds a proprietary computational platform for structure-based small-molecule drug design that replaces traditional high-throughput screening and library-based virtual screening with first-principles molecular generation. Its integrated platform comprises five purpose-built AI engines: Proteus for optimal protein conformation selection, Q-Pocket for binding pocket analysis using quantum-annotated hotspot clouds, the Denovo Platform for de novo molecule generation using generative AI and reinforcement learning, HADES (Holistic AI-based Drug-likeness Estimation System) for evaluating 100+ physicochemical, ADMET, and structural features, and Synthony for retrosynthesis planning using a building-block-first paradigm. Validated performance benchmarks include 50,000 compounds per week generation throughput, 89.1% drug-likeness prediction accuracy on external datasets, 74% top-1 retrosynthesis accuracy on USPTO50k, and experimentally confirmed in vitro and in vivo anti-influenza activity.

The company serves pharmaceutical companies, biotechnology firms, and academic research institutions seeking to accelerate early-stage drug discovery, particularly for targets where conventional and AI-based methods have struggled. It monetizes through three channels: software licensing (cloud, API, or on-premise deployment on a subscription basis), discovery services (hit finding, lead finding, lead optimization), and co-discovery/shared development partnerships with shared risk and licensing economics. Strategic partners include Flagship Pioneering, University of Oxford, Weill Cornell Medicine, and CIRI, with three co-founders (CEO Hovakim Zakaryan, CAIO Vardan Harutyunyan, CTO Mher Matevosyan) and an advisory board of senior pharma and AI veterans from GSK, J&J, and Insilico Medicine.

As of the available data, the company has 11-50 employees, has tested 300+ AI-generated molecules across 6 drug discovery programs with a 30% average hit rate, and operates on disclosed funding of approximately $626,236 across four rounds since 2020. No customer logos, ARR, or revenue figures are publicly disclosed.

Denovo Sciences firmographics

Firmographics
Name
Denovo Sciences
Legal name
Denovo Sciences
Website
https://denovosciences.ai
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Denovo Sciences is an Armenia-based AI drug discovery company building a proprietary platform of five integrated engines for de novo small-molecule design, serving pharmaceutical and biotechnology partners via software licensing, discovery services, and co-development partnerships.
Ownership category
akta.pro rank

Denovo Sciences industry classification

Industry
Product category
AI Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Computational drug design
  • Small-molecule therapeutics
  • Generative molecular design
  • Structure-based drug discovery

Where Denovo Sciences is headquartered

Location

Headquarters

HQ city
Yerevan
HQ country
Armenia
HQ region
Asia

Offices1 record

Markets served

Denovo Sciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Software Licensing: Access to proprietary AI-powered drug discovery technologies via cloud-based solutions, API integration, or on-premise deployment. Provides flexible deployment options for partners.
  2. Discovery Services: End-to-end drug discovery support including hit finding, lead finding, and lead optimization services leveraging the AI-driven platform.
  3. Co-Discovery/Shared Development Partnerships: Joint discovery and advancement of promising candidates from hit to preclinical stages with partners, enabling shared risk and reward in drug development.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels2 records

Denovo Sciences product offering

Product offering

Core offering

Denovo Sciences builds an AI-powered computational platform for structure-based small-molecule drug discovery. The integrated platform combines proprietary generative AI, retrosynthesis prediction (Synthony), drug-likeness evaluation (HADES), and target/binding-pocket analysis (Proteus, Q-Pocket) to design, evaluate, and prioritize novel drug-like compounds de novo within target binding pockets. The company also delivers discovery services and co-development partnerships to pharmaceutical and biotech clients.

Product overview

Denovo Sciences offers an AI-powered drug discovery platform comprising a core Denovo Platform generative engine plus multiple integrated modules: HADES for drug-likeness evaluation (100+ features), Synthony for retrosynthesis planning, Q-Pocket for binding pocket analysis, and Proteus for target conformation selection. These modules work together in an end-to-end workflow from target selection through synthesizable molecule generation and prioritization.

Differentiator

Problem solved

Functional benefit

Brands

  • Denovo Platform: AI-powered generative engine for small-molecule drug discovery, providing integrated molecular design, evaluation, and optimization workflows.
  • HADES
  • Synthony
  • Q-Pocket
  • Proteus

Products and services

  • Denovo Platform Core AI-powered generative engine platform for de novo small-molecule drug discovery; generates novel, synthesizable, drug-like compounds from first principles within target binding pockets, producing up to 50K compounds per week with 100% chemical validity. Sold to pharmaceutical and biotech partners via cloud, API, or on-premise deployment.
  • HADES (Holistic AI-based Drug-likeness Estimation System) Proprietary engine for rapid drug-likeness evaluation that integrates 100+ structural, physicochemical, ADMET, and chemical-alert features into a unified score with detailed rationales; assesses 20 molecules per second at 89.1% accuracy on external datasets. Used to prioritize generated compounds for drug development.
  • Synthony AI-driven retrosynthesis platform using a building-block-first paradigm to predict synthon sets from target structures, construct forward synthesis trees from purchasable building blocks, and score routes on feasibility, availability, cost, and commercial viability (74% top-1 accuracy on USPTO50k).
  • Q-Pocket Automated toolkit for binding pocket conformation selection using quantum-annotated hotspot clouds; benchmarks conformations against functional criteria and delivers sub-minute extraction and featurization for de novo generation readiness.
  • Proteus Proprietary platform that systematically analyzes and benchmarks all available protein conformations in the Protein Data Bank against known active compounds and decoys to recommend optimal target conformations for structure-based drug design.
  • Discovery Services End-to-end drug discovery service engagements including hit finding, lead finding, and lead optimization delivered to pharmaceutical and biotech partners using the Denovo AI platform.
  • Co-Discovery / Shared Development Partnerships Joint discovery and advancement partnerships where Denovo and a partner share risk and reward in moving candidates from hit stage to preclinical, combining Denovo's AI capabilities with partner resources and domain expertise.
  • Software Licensing (Cloud / API / On-Premise) Licensed access to the Denovo Platform, HADES, Synthony, Q-Pocket, and Proteus technologies delivered via cloud-based solutions, API integration into partner workflows, or on-premise deployment for organizations with data sovereignty or integration requirements.

Quantifiable outcome

  • 30% average hit rate across drug discovery programs
  • +3 more outcomes

Companies that use Denovo Sciences

Customer profile

Segments3 records

Ideal customer profiles3 records

Denovo Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Denovo Sciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Flagship PioneeringcoreStrategic or Co-development PartnerFlagship Pioneering is a prominent life sciences venture firm and innovation studio. The nature of the partnership with Denovo Sciences suggests strategic collaboration in the drug discovery space, potentially involving funding and strategic guidance for AI-powered pharmaceutical development.
  • CIRIcoreStrategic or Co-development PartnerCIRI appears to be a research institution or center involved in infectious disease research. The partnership likely focuses on collaborative antiviral drug discovery projects utilizing Denovo's AI platform.
  • ChuvcoreStrategic or Co-development PartnerChuv appears to be a research institution (likely referencing Chuvashia or a specific research center). The partnership enables access to academic research capabilities and validates the scientific rigor of Denovo's platform through institutional collaboration.
  • OxfordcoreStrategic or Co-development PartnerUniversity of Oxford is one of the world's leading research universities. The partnership provides academic validation, research collaboration opportunities, and access to cutting-edge scientific expertise in structural biology and drug discovery.
  • Weill CornellcoreStrategic or Co-development PartnerWeill Cornell Medicine is a leading medical research institution. The partnership supports translational research initiatives and provides clinical perspective for drug development programs.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Denovo Sciences competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: Direct competitor in AI-driven small-molecule drug discovery. Both companies combine generative chemistry, target ID, and predictive ADMET into end-to-end pipelines; Insilico's former CAIO (Artur Kadurin) sits on Denovo's advisory board, underscoring direct comparability.
  • Schrödinger, Inc. Operates a physics-based computational chemistry platform (including FEP+ and LiveDesign) that overlaps directly with Denovo's structure-based design and molecular modeling capabilities for pharma R&D.
  • Recursion Pharmaceuticals: AI-native drug discovery company combining high-throughput biology with machine learning to drive small-molecule pipelines; comparable as an end-to-end generative discovery platform targeting pharma partnerships and internal pipeline development.
  • Exscientia: Pioneer in AI-driven small-molecule drug design with an end-to-end platform and pharma co-discovery partnerships; directly comparable to Denovo's generative chemistry plus discovery services model.
  • Atomwise: AI small-molecule discovery platform serving pharma partners via software licensing and co-discovery — directly comparable GTM and technology footprint to Denovo's structure-based generative approach.
  • XtalPi: Combines AI, physics-based modeling, and robotic synthesis for small-molecule drug discovery; directly comparable on the integration of generative design with retrosynthesis and drug-likeness assessment (HADES/Synthony equivalents).

Emerging players

  • Iambic Therapeutics: Earlier-stage AI drug-discovery platform with comparable generative chemistry and physics-based modeling capabilities; overlaps with Denovo's structure-based design and ADMET prediction stack.
  • Aria Pharmaceuticals: AI-driven small-molecule discovery using integrated omics and chemistry ML; overlaps with Denovo's pharma partnership and indication-pivot strategy at similar early-stage scale.

Broad incumbents

  • Isomorphic Labs: Alphabet-backed AI-drug-discovery venture building an integrated platform from target ID to molecule design; broader in scope and capital but a comparable end-to-end generative drug-discovery vision.
  • BenevolentAI: Established AI-drug-discovery company combining knowledge graphs with ML to identify targets and small molecules; comparable in target-to-molecule scope, though typically more target-ID focused than Denovo's de novo design emphasis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Denovo Sciences social profiles

Digital presence

Denovo Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Denovo Sciences leadership team

Management profile

Number of profiles

Profiles6 records

Denovo Sciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Denovo Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Denovo Sciences

What does Denovo Sciences do?

Denovo Sciences builds an AI-powered computational platform for structure-based small-molecule drug discovery. The integrated platform combines proprietary generative AI, retrosynthesis prediction (Synthony), drug-likeness evaluation (HADES), and target/binding-pocket analysis (Proteus, Q-Pocket) to design, evaluate, and prioritize novel drug-like compounds de novo within target binding pockets. The company also delivers discovery services and co-development partnerships to pharmaceutical and biotech clients.

Is Denovo Sciences a public or private company?

Denovo Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Denovo Sciences founded?

Denovo Sciences was founded in 2019. It employs 11 to 50 people.

Where is Denovo Sciences based?

Denovo Sciences is headquartered in Yerevan, Armenia, in the Asia region.

How does Denovo Sciences make money?

Three revenue lines are on record. Software Licensing is the primary driver. The others are discovery Services and co-Discovery/Shared Development Partnerships.

Who are Denovo Sciences's main competitors?

Direct peers on record are Insilico Medicine, Schrödinger, Inc., Recursion Pharmaceuticals, Exscientia, Atomwise and XtalPi. Emerging players are Iambic Therapeutics and Aria Pharmaceuticals. Broad incumbents are Isomorphic Labs and BenevolentAI.

Does Denovo Sciences have an API?

No public API is recorded for Denovo Sciences.

What industry is Denovo Sciences in?

Denovo Sciences's product category is AI Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Digital Health NewsMankind Pharma Partners with Denovo Sciences to Advance AI-Led Drug DiscoveryMankind Pharma has partnered with Armenia-based Denovo Sciences to launch an AI-led drug discovery programme that combines Mankind Pharma's R&D and clinical development capabilities with Denovo Sciences' proprietary AI platform for molecular generation and prioritization. Under the human-in-the-loop model, AI will generate and evaluate molecular candidates while scientists validate and refine them throughout the discovery process. Both organisations aim to reduce early drug discovery timelines, improve lead candidate quality, and bring differentiated, effective therapies to patients sooner.Fortune IndiaMankind Pharma collaborates with Armenian Denovo Sciences for AI-led drug discovery programmeDomestic pharmaceutical major Mankind Pharma has partnered with Armenian startup Denovo Sciences to launch an AI-led drug discovery programme, combining Mankind's R&D capabilities and clinical development expertise with Denovo Sciences' proprietary AI-driven molecular generation platform. The collaboration employs a human-in-the-loop model where AI generates and evaluates molecular candidates while scientific experts guide, validate, and refine results, with stated goals of reducing early drug discovery timelines, improving lead candidate quality, and ensuring only the strongest candidates advance. Both organizations have indicated the long-term aim is to bring differentiated, effective, and accessible therapies to patients sooner through faster discovery cycles and better candidate selection.The Times of Indiamankind pharma: Mankind Pharma partners Denovo Sciences for AI-led drug discovery - The Economic TimesMankind Pharma announced a strategic collaboration with Denovo Sciences on July 2, 2026, to launch an AI-led drug discovery programme aimed at reducing early research timelines and improving the quality of potential drug candidates. The partnership combines Mankind Pharma's R&D capabilities and clinical development expertise with Denovo Sciences' AI-driven molecular generation and prioritization platform, operating under a human-in-the-loop model. The companies expect this collaboration to help bring differentiated, effective, and accessible therapies to patients faster, marking a significant step in innovation-driven research.BusinessLineMankind Pharma partners Denovo Sciences for AI-led drug discoveryMankind Pharma Ltd announced a strategic collaboration with Denovo Sciences to launch an AI-led drug discovery programme, marking an innovation-driven R&D focus for the company. The partnership aims to reduce early drug discovery timelines, improve lead candidate quality, and employ a human-in-the-loop model where AI generates and evaluates molecular candidates while scientific experts guide and validate results. The collaboration combines Mankind Pharma's R&D and clinical development expertise with Denovo Sciences' AI-driven molecular generation platform to bring differentiated therapies to patients more efficiently.The Times of IndiaAI-powered Drug Discovery: Mankind Pharma partners Denovo Sciences for AI-led drug discovery, ETManufacturingMankind Pharma announced a strategic partnership with Denovo Sciences to launch an AI-led drug discovery programme aimed at reducing early discovery timelines, improving lead candidate quality, and ensuring only the most promising candidates advance. The collaboration combines Mankind Pharma's R&D capabilities and clinical development expertise with Denovo Sciences' proprietary AI-driven molecular generation and prioritisation platform under a human-in-the-loop model. The companies expect faster discovery cycles and better candidate selection to help bring differentiated, effective, and accessible therapies to patients sooner.The Times of Indiamankind pharma: Mankind Pharma joins hands with Denovo Sciences for AI-powered drug discovery - The Economic TimesMankind Pharma Ltd announced a partnership with Denovo Sciences to launch an AI-driven drug discovery program, combining Mankind Pharma's R&D infrastructure and clinical validation expertise with Denovo Sciences' custom AI platform. The collaboration aims to cut early drug discovery timelines, enhance the quality of lead candidates, and filter out drugs with low success probability through computational accuracy at the start of the development process. The companies will operate under a human-in-the-loop model where AI generates molecular candidates while scientific experts validate and refine results at every stage.Fortune IndiaMankind Pharma collaborates with Armenian Denovo Sciences for AI-led drug discovery programmeIndian pharmaceutical company Mankind Pharma has partnered with Armenian startup Denovo Sciences to launch an AI-led drug discovery programme, combining Mankind's R&D, experimental validation, and clinical development capabilities with Denovo Sciences' AI-driven molecular generation platform. The collaboration operates under a human-in-the-loop model where AI generates and evaluates molecular candidates while scientific experts guide and validate results at every stage. The partnership aims to reduce early drug discovery timelines, improve lead candidate quality, and bring differentiated, effective, and accessible therapies to patients faster.EVN ReportDeep Tech Companies in Armenia: What Problems Do They Solve?Three Armenian Deep Tech companies—Krisp, Unum, and Denovo Sciences—are profiled for their technologies. Krisp filters noise and separates voices; Unum aims to move data processing to long-term memory; Denovo Sciences uses machine learning to design therapeutic molecules. The article notes challenges like a shortage of scientific specialists and calls for state support.AUA NewsroomDenovo Sciences & Zoomerang Win EWC Armenia 2021Denovo Sciences and Zoomerang won the EWC Armenia 2021 national finals, earning $20,000 each and advancing to the EWC Global Finals. The event, held on July 24 in Yerevan, featured 12 teams competing for over $100,000 in prizes. The global finals will take place in Riyadh in November.